Facile skin targeting of a thalidomide analog containing benzyl chloride moiety alleviates experimental psoriasis via the suppression of MAPK/NF- κB/AP-1 phosphorylation in keratinocytes

Psoriasis is an immune-mediated skin inflammation affecting 1% ∼4% of people worldwide [1,2]. More than 80% of patients show a mild-to-moderate level of severity [3], which can be controlled by topical therapy. Conventional topical application treatment is usually time-consuming with incomplete lesion resolution and some adverse effects. The development of ne w topically applied agents is needed.
Source: Journal of Dermatological Science - Category: Dermatology Authors: Source Type: research